Herman K. Gold - Concepedia

Author

Herman K. Gold

Also Known As

A. S. Jaffe, H K Gold, H. K. GOLD, H. K. Gold, H.K Gold, H.K. Gold, HERMAN GOLD, HERMAN K. GOLD, Herman Gold, Herman K Gold

237

Publications

25K

Citations

H-Index

135

Concepts

All Affiliations

Massachusetts General Hospital Harvard University KU Leuven University of Vermont

About

Herman K. Gold is an author at Massachusetts General Hospital specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	56	107	13.3K
2	Public Health	27	39	4K
3	Health Sciences	9	9	461
4	Engineering	4	4	275
5	Allergy	3	3	40

Herman K. Gold

146

Publications

20.9K

Citations

H-Index

Page 1

	Year	Citations
Pathology of Drug-Eluting Stents in Humans Michael Joner, Aloke V. Finn, Andrew Farb, Journal of the American College of Cardiology Percutaneous Coronary InterventionVascular DiseaseCardiovascular DiseasePharmacologyVascular Surgery	2006	2.7K
Intraplaque Hemorrhage and Progression of Coronary Atheroma Frank D. Kolodgie, Herman K. Gold, Allen Burke, New England Journal of Medicine	2003	1.5K
Pathological Correlates of Late Drug-Eluting Stent Thrombosis Aloke V. Finn, Michael Joner, Gaku Nakazawa, Circulation	2007	1.3K
Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents Michael Joner, Gaku Nakazawa, Aloke V. Finn, Journal of the American College of Cardiology Tissue EngineeringMedicineEndothelial DysfunctionVascular SurgeryLumen-apposing Metal Stent	2008	638
Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients Gaku Nakazawa, Aloke V. Finn, Michael Joner, Circulation	2008	607
Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents Aloke V. Finn, Frank D. Kolodgie, Jan Harnek, Circulation	2005	557
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Ik–Kyung Jang, Herman K. Gold, Andrew A. Ziskind, Circulation Platelet-rich Arterial ThrombiBiomedical EngineeringAcute Myocardial InfarctionThrombosisHematology	1989	554
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Herman K. Gold, Barry S. Coller, Tsunehiro Yasuda, Circulation Single Bolus InjectionsBolus InjectionsPrevent ReocclusionCombined Bolus InjectionBiomedical Engineering	1988	393
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. D Collen, Eric J. Topol, Alan J. Tiefenbrunn, Circulation Fibrinogen LevelPlacebo-controlled TrialCoronary Artery DiseaseAcute Myocardial InfarctionThrombosis	1984	385
Major Depression Is Associated with Significant Diurnal Elevations in Plasma Interleukin-6 Levels, a Shift of Its Circadian Rhythm, and Loss of Physiological Complexity in Its Secretion: Clinical Implications Salvatore Alesci, Pedro E. Martinez, Sujata Kelkar, The Journal of Clinical Endocrinology & Metabolism	2005	373

Page 1